Search

Your search keyword '"Sportoletti, Paolo"' showing total 665 results
Start Over Author "Sportoletti, Paolo"
665 results on '"Sportoletti, Paolo"'

51. Supplementary Figures S1 - S5 from A Genetic Platform to Model Sarcomagenesis from Primary Adult Mesenchymal Stem Cells

Author

Guarnerio, Jlenia, primary, Riccardi, Luisa, primary, Taulli, Riccardo, primary, Maeda, Takahiro, primary, Wang, Guocan, primary, Hobbs, Robin M., primary, Song, Min Sup, primary, Sportoletti, Paolo, primary, Bernardi, Rosa, primary, Bronson, Roderick T., primary, Castillo-Martin, Mireia, primary, Cordon-Cardo, Carlos, primary, Lunardi, Andrea, primary, and Pandolfi, Pier Paolo, primary

Published
2023
Full Text
View/download PDF

52. Figure S10 from Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia

Author

Del Papa, Beatrice, primary, Baldoni, Stefano, primary, Dorillo, Erica, primary, De Falco, Filomena, primary, Rompietti, Chiara, primary, Cecchini, Debora, primary, Cantelmi, Maria Grazia, primary, Sorcini, Daniele, primary, Nogarotto, Manuel, primary, Adamo, Francesco Maria, primary, Mezzasoma, Federica, primary, Silva Barcelos, Estevão Carlos, primary, Albi, Elisa, primary, Iacucci Ostini, Roberta, primary, Di Tommaso, Ambra, primary, Marra, Andrea, primary, Montanaro, Guido, primary, Martelli, Maria Paola, primary, Falzetti, Franca, primary, Di Ianni, Mauro, primary, Rosati, Emanuela, primary, and Sportoletti, Paolo, primary

Published
2023
Full Text
View/download PDF

53. High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the GIMEMA phase II LLC1518 - 'Veritas' study

Author

Mauro, Francesca R, Starza, Irene Della, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Casaluci, Gloria Margiotta, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Ilariucci, Fiorella, Stelitano, Caterina, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfò, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Patrizi, Valeria Belsito, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pietrasanta, Daniela, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Novi, Lucia Anna, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin, Laurenti, Luca (ORCID:0000-0002-8327-1396), Mauro, Francesca R, Starza, Irene Della, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Casaluci, Gloria Margiotta, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Ilariucci, Fiorella, Stelitano, Caterina, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfò, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Patrizi, Valeria Belsito, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pietrasanta, Daniela, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Novi, Lucia Anna, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

The GIMEMA phase II LLC1518 VERITAS trial investigated the efficacy and safety of frontline, fixed-duration venetoclax and rituximab (VenR) combination in young (≤65 years) and fit patients with chronic lymphocytic leukemia (CLL) and unmutated IGHV and/or TP53 disruption. Treatment consisted of the Ven ramp-up, six-monthly courses of the VenR combination, followed by six monthly courses of Ven single agent. A centralized assessment of measurable minimal residual disease (MRD) was performed on the peripheral blood (PB) and bone marrow (BM) by ASO-PCR at the end of treatment (EOT) and during the follow-up. The primary endpoint was the complete remission (CR) rate at the EOT. Seventy-five patients were enrolled; the median age was 54 years (range 38-65), 96% had unmutated IGHV, 9 (12%) had TP53 disruption, and 4% were IGHV mutated with TP53 disruption. The overall response rate (ORR) at the EOT was 94.7%, with a CR rate of 76%. An undetectable (u) MRD was recorded in 69.3% of patients in the PB and 58.7% in the BM. The 12-month MRD-free survival in the 52 patients with uMRD in the PB at the EOT was 73.1%. After a median follow-up of 20.8 months, no disease progressions were observed. Three patients have died, two due to Covid-19 and 1 to tumor lysis syndrome. The first report of the VERITAS study shows that frontline VenR was associated with a high rate of CRs and durable responses with uMRD in young patients with CLL and unfavorable genetic characteristics.

Published
2023

54. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

Author

AbbVie Pharmaceuticals, European Commission, Chatzikonstantinou, Thomas, Scarfò, Lydia, Karakatsoulis, Georgios, Minga, Eva, Chamou, Dimitra, Iacoboni, Gloria, Kotaskova, Jana, Demosthenous, Christos, Smolej, Lukas, Mulligan, Stephen, Alcoceba, Miguel, Kreitman, Robert J., Labrador, Jorge, Lad, Deepesh, Levin, Mark-David, Levy, Ilana, Longval, Thomas, López-García, Alberto, Marquet, Juan, Martín-Rodríguez, Lucía, Maynadié, Marc, Tadmor, Tamar, Maslejova, Stanislava, Mayor-Bastida, Carlota, Mihaljevic, Biljana, Milosevic, Ivana, Mirás, Fátima, Moia, Riccardo, Morawska, Marta, Murru, Roberta, Nath, Uttam Kumar, Navarro-Bailón, Almudena, Tomic, Kristina, Oliveira, Ana C., Olivieri, Jacopo, Oscier, David, Panovska-Stavridis, Irina, Papaioannou, María, Papajík, Tomás, Kubova, Zuzana, Phumphukhieo, Punyarat, Pierie, Cheyenne, Puiggros, Anna, Tse, Eric, Rani, Lata, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Daniel de Deus Santos, Marcos, Schipani, Mattia, Schiwitza, Annett, Shen, Yandong, Simkovic, Martín, Smirnova, Svetlana, Vassilakopoulos, Theodoros, Abdelrahman Soliman, Dina Sameh, Spacek, Martin, Visentin, Andrea, Vitale, Candida, von Tresckow, Julia, Vrachiolias, George, Vukovic, Vojin, Walewska, Renata, Al-Shemari, Salem, Wasik-Szczepanek, Ewa, Xu, Zhenshu, Yagci, Munci, Yañez, Lucrecia, Yassin, Mohamed, Zuchnicka, Jana, Angelopoulou, Maria, Antic, Darko, Biderman, Bella, Catherwood, Mark, Aurran-Schleinitz, Thérèse, Claus, Rainer, Coscia, Marta, Cuneo, Antonio, Demirkan, Fatih, Espinet, Blanca, Gaidano, Gianluca, Kalashnikova, Olga B., Laurenti, Luca, Nikitin, Eugene, Pangalis, Gerassimos A., Bacchiarri, Francesca, Panagiotidis, Panagiotis, Popov, Viola María, Pospisilova, Sarka, Sportoletti, Paolo, Stavroyianni, Niki, Tam, Constantine S., Trentin, Livio, Chatzidimitriou, Anastasia, Bosch, Francesc, Doubek, Michael, Bellido, Mar, Ghia, Paolo, Stamatopoulos, Kostas, Bijou, Fontanet, Calleja, Anne, Medina, Angeles, Khan, Mehreen Ali, Cassin, Ramona, Chatzileontiadou, Sofía, Collado, Rosa, Christian, Amy, Davis, Zadie, Dimou, María, Donaldson, David, Santos, Gimena Dos, Dreta, Bárbara, Efstathopoulou, María, El-Ashwah, Shaimaa, Enrico, Alicia, Fresa, Alberto, Galimberti, Sara, Galitzia, Andrea, García-Serra, Rocío, Gimeno, Eva, González-Gascón y Marín, Isabel, Gozzetti, Alessandro, Guarente, Valerio, Guieze, Romain, Gogia, Ajay, Gupta, Ritu, Harrop, Sean, Hatzimichael, Eleftheria, Herishanu, Yair, Hernández-Rivas, José Ángel, Inchiappa, Luca, Jaksic, Ozren, Janssen, Susanne, Kalicińska, Elżbieta, Kamel, Laribi, Karakus, Volkan, Kater, Arnon P., Kho, Bonnie, Kislova, María, Konstantinou, Eliana, Koren-Michowitz, Maya, Kotsianidis, Ioannis, AbbVie Pharmaceuticals, European Commission, Chatzikonstantinou, Thomas, Scarfò, Lydia, Karakatsoulis, Georgios, Minga, Eva, Chamou, Dimitra, Iacoboni, Gloria, Kotaskova, Jana, Demosthenous, Christos, Smolej, Lukas, Mulligan, Stephen, Alcoceba, Miguel, Kreitman, Robert J., Labrador, Jorge, Lad, Deepesh, Levin, Mark-David, Levy, Ilana, Longval, Thomas, López-García, Alberto, Marquet, Juan, Martín-Rodríguez, Lucía, Maynadié, Marc, Tadmor, Tamar, Maslejova, Stanislava, Mayor-Bastida, Carlota, Mihaljevic, Biljana, Milosevic, Ivana, Mirás, Fátima, Moia, Riccardo, Morawska, Marta, Murru, Roberta, Nath, Uttam Kumar, Navarro-Bailón, Almudena, Tomic, Kristina, Oliveira, Ana C., Olivieri, Jacopo, Oscier, David, Panovska-Stavridis, Irina, Papaioannou, María, Papajík, Tomás, Kubova, Zuzana, Phumphukhieo, Punyarat, Pierie, Cheyenne, Puiggros, Anna, Tse, Eric, Rani, Lata, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Daniel de Deus Santos, Marcos, Schipani, Mattia, Schiwitza, Annett, Shen, Yandong, Simkovic, Martín, Smirnova, Svetlana, Vassilakopoulos, Theodoros, Abdelrahman Soliman, Dina Sameh, Spacek, Martin, Visentin, Andrea, Vitale, Candida, von Tresckow, Julia, Vrachiolias, George, Vukovic, Vojin, Walewska, Renata, Al-Shemari, Salem, Wasik-Szczepanek, Ewa, Xu, Zhenshu, Yagci, Munci, Yañez, Lucrecia, Yassin, Mohamed, Zuchnicka, Jana, Angelopoulou, Maria, Antic, Darko, Biderman, Bella, Catherwood, Mark, Aurran-Schleinitz, Thérèse, Claus, Rainer, Coscia, Marta, Cuneo, Antonio, Demirkan, Fatih, Espinet, Blanca, Gaidano, Gianluca, Kalashnikova, Olga B., Laurenti, Luca, Nikitin, Eugene, Pangalis, Gerassimos A., Bacchiarri, Francesca, Panagiotidis, Panagiotis, Popov, Viola María, Pospisilova, Sarka, Sportoletti, Paolo, Stavroyianni, Niki, Tam, Constantine S., Trentin, Livio, Chatzidimitriou, Anastasia, Bosch, Francesc, Doubek, Michael, Bellido, Mar, Ghia, Paolo, Stamatopoulos, Kostas, Bijou, Fontanet, Calleja, Anne, Medina, Angeles, Khan, Mehreen Ali, Cassin, Ramona, Chatzileontiadou, Sofía, Collado, Rosa, Christian, Amy, Davis, Zadie, Dimou, María, Donaldson, David, Santos, Gimena Dos, Dreta, Bárbara, Efstathopoulou, María, El-Ashwah, Shaimaa, Enrico, Alicia, Fresa, Alberto, Galimberti, Sara, Galitzia, Andrea, García-Serra, Rocío, Gimeno, Eva, González-Gascón y Marín, Isabel, Gozzetti, Alessandro, Guarente, Valerio, Guieze, Romain, Gogia, Ajay, Gupta, Ritu, Harrop, Sean, Hatzimichael, Eleftheria, Herishanu, Yair, Hernández-Rivas, José Ángel, Inchiappa, Luca, Jaksic, Ozren, Janssen, Susanne, Kalicińska, Elżbieta, Kamel, Laribi, Karakus, Volkan, Kater, Arnon P., Kho, Bonnie, Kislova, María, Konstantinou, Eliana, Koren-Michowitz, Maya, and Kotsianidis, Ioannis

Abstract

[Background]: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work., [Methods]: We conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022., [Findings]: In 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs). The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79–4.91; p < 0.001). STs were more frequent in males and patients with unmutated immunoglobulin heavy variable genes (OR = 1.77; 95% CI = 1.49–2.11; p < 0.001/OR = 1.89; 95% CI = 1.6–2.24; p < 0.001). CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36–2.41; p < 0.001/OR = 2.11; 95% CI = 1.12–3.97; p = 0.021). In contrast, breast cancers were more frequent in untreated patients (OR = 0.17; 95% CI = 0.08–0.33; p < 0.001). Patients with CLL and an OM had inferior overall survival (OS) than those without. AML and MDS conferred the worst OS (p < 0.001)., [Interpretation]: OMs in CLL impact on OS. Treatment for CLL increased the risk for AML/MDS, prostate cancer, and NMSC. FCR was associated with increased risk for AML/MDS.

Published
2023

55. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Author

Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Scarfò, Lydia, Karakatsoulis, Georgios, Allsup, David, Cabrero, Alejandro Alonso, Andres, Martin, Antic, Darko, Baile, Mónica, Baliakas, Panagiotis, Bron, Dominique, Capasso, Antonella, Chatzileontiadou, Sofia, Cordoba, Raul, Correa, Juan-Gonzalo, Cuéllar-García, Carolina, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Demosthenous, Christos, Dimou, Maria, Donaldson, David, Doubek, Michael, Efstathopoulou, Maria, Eichhorst, Barbara, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Frederiksen, Henrik, Fürstenau, Moritz, García-Marco, José A., García-Serra, Rocío, Gentile, Massimo, Gimeno, Eva, Glenthøj, Andreas, Gomes da Silva, Maria, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Hernández-Rivas, José Ángel, Herold, Tobias, Innocenti, Idanna, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Оlga B., Kalicińska, Elżbieta, Karlsson, Linda Katharina, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Lopez-Garcia, Alberto, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mattsson, Mattias, Mauro, Francesca R., Milosevic, Ivana, Mirás, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Niemann, Carsten U., Rodrigues, Raquel Nunes, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Qvist, Kristian, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Saghumyan, Gevorg, Shrestha, Amit, Šimkovič, Martin, Špaček, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Tadmor, Tamar, Te Raa, Doreen, Tonino, Sanne H., Trentin, Livio, Van Der Spek, Ellen, van Gelder, Michel, van Kampen, Roel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Wasik-Szczepanek, Ewa, Wróbel, Tomasz, San Segundo, Lucrecia Yáñez, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foà, Robin, Cuneo, Antonio, Stamatopoulos, Kostas, and Ghia, Paolo

Abstract

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p< 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41–0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02–1.04; HR = 1.79, 95% CI:1.04–3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

Published
2024
Full Text
View/download PDF

56. NOTCH1-mutated chronic lymphocytic leukemia displays high endoplasmic reticulum stress response with druggable potential.

Author

Barcelos, Estevão Carlos Silva, Rompietti, Chiara, Adamo, Francesco Maria, Dorillo, Erica, De Falco, Filomena, Del Papa, Beatrice, Baldoni, Stefano, Nogarotto, Manuel, Esposito, Angela, Capoccia, Silvia, Geraci, Clelia, Sorcini, Daniele, Stella, Arianna, Arcaleni, Roberta, Tini, Valentina, Valle Errera, Flávia Imbroisi, Rosati, Emanuela, and Sportoletti, Paolo

Subjects
CHRONIC lymphocytic leukemia, CHRONIC leukemia, ENDOPLASMIC reticulum, GENE ontology, UNFOLDED protein response, POLYMERASE chain reaction, B cells
Abstract

Introduction: Constitutive activation of NOTCH1-wild-type (NT1-WT) signaling is associated with poor outcomes in chronic lymphocytic leukemia (CLL), and NOTCH1 mutation (c.7541_7542delCT), which potentiates NOTCH1 signaling, worsens the prognosis. However, the specific mechanisms of NOTCH1 deregulation are still poorly understood. Accumulative evidence mentioned endoplasmic reticulum (ER) stress/unfolded protein response (UPR) as a key targetable pathway in CLL. In this study, we investigated the impact of NOTCH1 deregulation on CLL cell response to ER stress induction, with the aim of identifying new therapeutic opportunities for CLL. Methods: We performed a bioinformatics analysis of NOTCH1-mutated (NT1-M) and NT1-WT CLL to identify differentially expressed genes (DEGs) using the rank product test. Quantitative real-time polymerase chain reaction (qPCR), Western blotting, cytosolic Ca2+, and annexin V/propidium iodide (PI) assay were used to detect curcumin ER stress induction effects. A median-effect equation was used for drug combination tests. The experimental mouse model E -TCL1 was used to evaluate the impact of ER stress exacerbation by curcumin treatment on the progression of leukemic cells and NOTCH1 signaling. Results and discussion: Bioinformatics analysis revealed gene enrichment of the components of the ER stress/UPR pathway in NT1-M compared to those in NT1- WT CLL. Ectopic expression of NOTCH1 mutation upregulated the levels of ER stress response markers in the PGA1 CLL cell line. Primary NT1-M CLL was more sensitive to curcumin as documented by a significant perturbation in Ca2+ homeostasis and higher expression of ER stress/UPR markers compared to NT1-WT cells. It was also accompanied by a significantly higher apoptotic response mediated by C/EBP homologous protein (CHOP) expression, caspase 4 cleavage, and downregulation of NOTCH1 signaling in NT1-M CLL cells. Curcumin potentiated the apoptotic effect of venetoclax in NT1-M CLL cells. In E -TCL1 leukemic mice, the administration of curcumin activated ER stress in splenic B cells ex vivo and significantly reduced the percentage of CD19+/CD5+ cells infiltrating the spleen, liver, and bone marrow (BM). These cellular effects were associated with reduced NOTCH1 activity in leukemic cells and resulted in prolonged survival of curcumin-treated mice. Overall, our results indicate that ER stress induction in NT1-M CLL might represent a new therapeutic opportunity for these high-risk CLL patients and improve the therapeutic effect of drugs currently used in CLL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

57. Continuous venetoclax in treatment‐naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.

Author

Visentin, Andrea, Mauro, Francesca Romana, Scarfò, Lydia, Gentile, Massimo, Farina, Lucia, Reda, Gianluigi, Ferrarini, Isacco, Proietti, Giulia, Derenzini, Enrico, Cibien, Francesca, Vitale, Candida, Sanna, Alessandro, Pietrasanta, Daniela, Marchetti, Monia, Murru, Roberta, Rigolin, Gian Matteo, Sportoletti, Paolo, Trimarco, Valentina, Cavarretta, Chiara Adele, and Angotzi, Francesco

Published
2023
Full Text
View/download PDF

58. High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study

Author

Mauro, Francesca R., primary, Starza, Irene Della, additional, Messina, Monica, additional, Reda, Gianluigi, additional, Trentin, Livio, additional, Coscia, Marta, additional, Sportoletti, Paolo, additional, Orsucci, Lorella, additional, Arena, Valentina, additional, Casaluci, Gloria Margiotta, additional, Marasca, Roberto, additional, Murru, Roberta, additional, Laurenti, Luca, additional, Ilariucci, Fiorella, additional, Stelitano, Caterina, additional, Mannina, Donato, additional, Massaia, Massimo, additional, Rigolin, Gian Matteo, additional, Scarfò, Lydia, additional, Marchetti, Monia, additional, Levato, Luciano, additional, Tani, Monica, additional, Arcari, Annalisa, additional, Musuraca, Gerardo, additional, Deodato, Marina, additional, Galieni, Piero, additional, Patrizi, Valeria Belsito, additional, Gottardi, Daniela, additional, Liberati, Anna Marina, additional, Giordano, Annamaria, additional, Molinari, Maria Chiara, additional, Pietrasanta, Daniela, additional, Mattiello, Veronica, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Albano, Francesco, additional, Neri, Antonino, additional, De Novi, Lucia Anna, additional, De Propris, Maria Stefania, additional, Nanni, Mauro, additional, Del Giudice, Ilaria, additional, Guarini, Anna, additional, Fazi, Paola, additional, Vignetti, Marco, additional, Piciocchi, Alfonso, additional, Cuneo, Antonio, additional, and Foà, Robin, additional

Published
2023
Full Text
View/download PDF

63. Immune correlates of protection by vaccine against SARS‐CoV ‐2 in patients with chronic lymphocytic leukaemia

Author

Sorcini, Daniele, primary, De Falco, Filomena, additional, Gargaro, Marco, additional, Bozza, Silvia, additional, Guarente, Valerio, additional, Cardinali, Valeria, additional, Stella, Arianna, additional, Adamo, Francesco Maria, additional, Silva Barcelos, Estevao Carlos, additional, Rompietti, Chiara, additional, Dorillo, Erica, additional, Geraci, Clelia, additional, Esposito, Angela, additional, Arcaleni, Roberta, additional, Capoccia, Silvia, additional, Mameli, Maria Grazia, additional, Graziani, Alessandro, additional, Moretti, Lorenzo, additional, Cipiciani, Alessandra, additional, Riccardi, Carlo, additional, Mencacci, Antonella, additional, Fallarino, Francesca, additional, Rosati, Emanuela, additional, and Sportoletti, Paolo, additional

Published
2022
Full Text
View/download PDF

64. Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “ Real‐World ” study

Author

Levi, Shai, primary, Bronstein, Yotam, additional, Goldschmidt, Neta, additional, Morabito, Fortunato, additional, Ziv‐Baran, Tomer, additional, Del Poeta, Giovanni, additional, Bairey, Osnat, additional, Del Principe, Maria Ilaria, additional, Fineman, Riva, additional, Mauro, Francesca Romana, additional, Gutwein, Odit, additional, Reda, Gianluigi, additional, Ruchlemer, Rosa, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Shvidel, Lev, additional, Coscia, Marta, additional, Tadmor, Tamar, additional, Varettoni, Marzia, additional, Aviv, Ariel, additional, Murru, Roberta, additional, Braester, Andrei, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Olivieri, Jacopo, additional, Neri, Antonio, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Trentin, Livio, additional, Foà, Robin, additional, Cuneo, Antonio, additional, Perry, Chava, additional, Gattei, Valter, additional, Gentile, Massimo, additional, and Herishanu, Yair, additional

Published
2022
Full Text
View/download PDF

65. Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study

Author

Visentin, Andrea, primary, Mauro, Francesca Romana, additional, Catania, Gioachino, additional, Fresa, Alberto, additional, Vitale, Candida, additional, Sanna, Alessandro, additional, Mattiello, Veronica, additional, Cibien, Francesca, additional, Sportoletti, Paolo, additional, Gentile, Massimo, additional, Rigolin, Gian Matteo, additional, Quaglia, Francesca Maria, additional, Murru, Roberta, additional, Gozzetti, Alessandro, additional, Molica, Stefano, additional, Marchetti, Monia, additional, Pravato, Stefano, additional, Angotzi, Francesco, additional, Cellini, Alessandro, additional, Scarfò, Lydia, additional, Reda, Gianluigi, additional, Coscia, Marta, additional, Laurenti, Luca, additional, Ghia, Paolo, additional, Foà, Robin, additional, Cuneo, Antonio, additional, and Trentin, Livio, additional

Published
2022
Full Text
View/download PDF

66. Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study Evidence

Author

Molica, Stefano, primary, Scalzulli, Potito Rosario, additional, Scarfò, Lydia, additional, Guarini, Attilio, additional, Murru, Roberta, additional, Sportoletti, Paolo, additional, Frigeri, Ferdinando, additional, Albano, Francesco, additional, Di Renzo, Nicola, additional, Sanna, Alessandro, additional, Innocenti, Idanna, additional, Massaia, Massimo, additional, Coscia, Marta, additional, Pennese, Elsa, additional, Patti, Caterina, additional, Reda, Gianluigi, additional, Tafuri, Agostino, additional, Regazzoni, Giulia, additional, Di Candia, Michele, additional, and Mauro, Francesca Romana, additional

Published
2022
Full Text
View/download PDF

67. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Author

Visentin, Andrea, primary, Scarfò, Lydia, additional, Chatzikonstantinou, Thomas, additional, Kapetanakis, Anargyros, additional, Demosthenous, Christos, additional, Karakatsoulis, Georgios, additional, Andres, Martin, additional, Antic, Darko, additional, Allsup, David, additional, Baile, Mónica, additional, Bron, Dominique, additional, Capasso, Antonella, additional, Catherwood, Mark, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Delgado, Julio, additional, Dimou, Maria, additional, Doubek, Michael, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Del Poeta, Giovanni, additional, Efstathopoulou, Maria, additional, Shimaa, El-Ashwah, additional, Enrico, Alicia, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Furstenau, Moritz, additional, Garcia-Marco, Jose A., additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Maria, Gomes da Silva, additional, Gutwein, Odit, additional, Hakobyan, Yervand, additional, Herishanu, Yair, additional, Hernandez, jose Angel, additional, Herold, Tobias, additional, Iyengar, Sunil, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Olga, additional, Kalicinska, Elzbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Levin, Mark-David, additional, Lista, Enrico, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet Palomanes, Juan, additional, Mattsson, Mattias, additional, Mauro, Francesca Romana, additional, Mayor-Bastida, Carlota, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Milosevic, Ivana, additional, Miras Calvo, Fatima, additional, Niemann, Carsten Utoft, additional, Olivieri, Jacopo, additional, Orsucci, Lorella, additional, Papaioannou, Maria, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga S., additional, Pocali, Barbara, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Raa, Doreen te, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca Ciocan, Oana, additional, Tadmor, Tamar, additional, Vandenberghe, Elisabeth, additional, Varettoni, Marzia, additional, Vitale, Candida, additional, Van Der Spek, Ellen, additional, Van Gelder, Michel, additional, Wasik-Szczepanek, Ewa, additional, Yáñez, Lucrecia, additional, Yassin, Mohamed A, additional, Coscia, Marta, additional, Eichhorst, Barbara, additional, Rambaldi, Alessandro, additional, Stavroyianni, Niki, additional, Trentin, Livio, additional, Stamatopoulos, Kostas, additional, and Ghia, Paolo, additional

Published
2022
Full Text
View/download PDF

68. Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Author

Antic, Darko, primary, Milic, Natasa, additional, Chatzikonstantinou, Thomas, additional, Scarfò, Lydia, additional, Otasevic, Vladimir, additional, Rajovic, Nina, additional, Allsup, David, additional, Cabrero, Alejandro Alonso, additional, Andres, Martin, additional, Baile Gonzales, Monica, additional, Capasso, Antonella, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Correa, Juan Gonzalo, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Del Poeta, Giovanni, additional, Dimou, Maria, additional, Doubek, Michael, additional, Efstathopoulou, Maria, additional, El-Ashwah, Shaimaa, additional, Enrico, Alicia, additional, Espinet, Blanca, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Lopez-Garcia, Alberto, additional, Garcia-Marco, Jose A., additional, García-Serra, Rocío, additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Gomes da Silva, Maria, additional, Gutwein, Odit, additional, Hakobyan, Yervand, additional, Herishanu, Yair, additional, Hernández-Rivas, José Ángel, additional, Herold, Tobias, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Оlga B., additional, Kalicińska, Elżbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Koren-Michowitz, Maya, additional, Gomez, Jorge Labrador, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Fresa, Alberto, additional, Levin, Mark-David, additional, Mayor Bastida, Carlota, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet, Juan, additional, Mihaljevic, Biljana, additional, Milosevic, Ivana, additional, Mirás, Fatima, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Nunes, Raquel, additional, Olivieri, Jacopo, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga S., additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Smirnova, Svetlana, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca, Oana, additional, Stavroyianni, Niki, additional, Te Raa, Doreen, additional, Tomic, Kristina, additional, Tonino, Sanne, additional, Trentin, Livio, additional, Van Der Spek, Ellen, additional, van Gelder, Michel, additional, Varettoni, Marzia, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Vukovic, Vojin, additional, Wasik-Szczepanek, Ewa, additional, Wróbel, Tomasz, additional, Yanez San Segundo, Lucrecia, additional, Yassin, Mohamed A, additional, Coscia, Marta, additional, Rambaldi, Alessandro, additional, Montserrat, Emili, additional, Foà, Robin, additional, Cuneo, Antonio, additional, Carrier, Marc, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2022
Full Text
View/download PDF

69. Continuous Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia and TP53 Abnormalities. a Study of the Italian Campus CLL

Author

Visentin, Andrea, primary, Mauro, Francesca, additional, Scarfò, Lydia, additional, Gentile, Massimo, additional, Farina, Lucia, additional, Reda, Gianluigi, additional, Ferrarini, Isacco, additional, Proietti, Giulia, additional, Derenzini, Enrico, additional, Cibien, Francesca, additional, Vitale, Candida, additional, Sanna, Alessandro, additional, Catania, Gioachino, additional, Marchetti, Monia, additional, Murru, Roberta, additional, Rigolin, Gian Matteo, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Molica, Stefano, additional, Coscia, Marta, additional, Ghia, Paolo, additional, Foa, Robin, additional, Cuneo, Antonio, additional, and Trentin, Livio, additional

Published
2022
Full Text
View/download PDF

70. Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Author

Capodanno, Isabella, primary, Tiribelli, Mario, additional, Miggiano, Maria Cristina, additional, Bucelli, Cristina, additional, Cavazzini, Francesco, additional, Leonetti Crescenzi, Sabrina, additional, Russo, Sabina, additional, Scalzulli, Emilia, additional, Bernardelli, Andrea, additional, Luciano, Luigiana, additional, Mulas, Olga, additional, Loglisci, Giuseppina, additional, Elena, Chiara, additional, Pizzano, Umberto, additional, Attolico, Immacolata, additional, Binotto, Gianni, additional, Crisà, Elena, additional, Sportoletti, Paolo, additional, Di Veroli, Ambra, additional, Scortechini, Anna Rita, additional, Leporace, Annapaola, additional, Basile, Maria, additional, Crugnola, Monica, additional, Stagno, Fabio, additional, Murgano, Pamela, additional, Rapezzi, Davide, additional, Luzi, Debora, additional, Iurlo, Alessandra, additional, Bocchia, Monica, additional, Fava, Carmen, additional, Malato, Alessandra, additional, Galimberti, Sara, additional, Vincelli, Iolanda Donatella, additional, Trawinska, Malgorzata Monika, additional, Pizzuti, Michele, additional, Caocci, Giovanni, additional, Bonifacio, Massimiliano, additional, Saglio, Giuseppe, additional, Specchia, Giorgina, additional, Breccia, Massimo, additional, and Latagliata, Roberto, additional

Published
2022
Full Text
View/download PDF

71. Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

Author

Stagno, Fabio, primary, Abruzzese, Elisabetta, additional, Iurlo, Alessandra, additional, Pane, Fabrizio, additional, Attolico, Imma, additional, Sportoletti, Paolo, additional, Pregno, Patrizia, additional, Galimberti, Sara, additional, Scappini, Barbara, additional, Miglino, Maurizio, additional, Siragusa, Sergio, additional, Capodanno, Isabella, additional, Valsecchi, Diletta, additional, Nardozza, Aurelio Pio, additional, Coco, Paola, additional, Rosti, Gianantonio, additional, Saglio, Giuseppe, additional, and Breccia, Massimo, additional

Published
2022
Full Text
View/download PDF

72. How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia

Author

Frustaci, Annamaria, primary, Piazza, Francesco, additional, Ferrero, Simone, additional, Reda, Gianluigi, additional, Rizzi, Rita, additional, Orsucci, Lorella, additional, Ferrarini, Isacco, additional, Deodato, Marina, additional, Laurenti, Luca, additional, Puccini, Benedetta, additional, Baratè, Claudia, additional, Varettoni, Marzia, additional, Merli, Michele, additional, Cencini, Emanuele, additional, Greco, Antonino, additional, Gini, Guido, additional, Ferrari, Angela, additional, Borella, Chiara, additional, Lista, Enrico, additional, Gentile, Massimo, additional, Murru, Roberta, additional, Motta, Marina, additional, Rezzonico, Francesca, additional, Tani, Monica, additional, Sportoletti, Paolo, additional, Zamprogna, Giulia, additional, Torri, Valter, additional, Cairoli, Roberto, additional, and Tedeschi, Alessandra, additional

Published
2022
Full Text
View/download PDF

73. Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Author

Breccia, Massimo, primary, Guglielmelli, Paola, additional, Mendicino, Francesco, additional, Malato, Alessandra, additional, Palumbo, Giuseppe A., additional, Selleri, Carmine, additional, Cilloni, Daniela, additional, Mazza, Patrizio, additional, Siragusa, Sergio, additional, Abruzzese, Elisabetta, additional, Martelli, Maurizio, additional, Benevolo, Giulia, additional, Rinaldi, Erminia, additional, Crugnola, Monica, additional, Rupoli, Serena, additional, Pavone, Vincenzo, additional, Bonifacio, Massimiliano, additional, Pane, Fabrizio, additional, Carli, Giuseppe, additional, Langella, Maria, additional, Bruno Ventre, Marta, additional, Elli, Elena Maria, additional, Impera, Stefana, additional, Liberati, Anna Marina, additional, Di Renzo, Nicola, additional, Martino, Bruno, additional, Sportoletti, Paolo, additional, Tiribelli, Mario, additional, Binotto, Gianni, additional, Annunziata, Mario, additional, Di Ianni, Mauro, additional, La Nasa, Giorgio, additional, Falcone, Antonietta Pia, additional, Leanza, Rossana, additional, Volpe, Antonio, additional, Gherlinzoni, Filippo, additional, De Stefano, Valerio, additional, Vallisa, Daniele, additional, Leonetti Crescenzi, Sabrina, additional, Cavazzini, Francesco, additional, Ricco, Alessandra, additional, Barberio, Carmela, additional, Misto, Alessandra, additional, Passamonti, Francesco, additional, and Palandri, Francesca, additional

Published
2022
Full Text
View/download PDF

74. Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study

Author

Fresa, Alberto, primary, Autore, Francesco, additional, Piciocchi, Alfonso, additional, Catania, Gioacchino, additional, Visentin, Andrea, additional, Tomasso, Annamaria, additional, Moretti, Marina, additional, Vitale, Candida, additional, Chiarenza, Annalisa, additional, Morelli, Francesca, additional, Sportoletti, Paolo, additional, Marasca, Roberto, additional, Sapienza, Giuseppe, additional, Cuccaro, Annarosa, additional, Murru, Roberta, additional, Sanna, Alessandro, additional, Patti, Caterina, additional, Angeletti, Ilaria, additional, Coscia, Marta, additional, Trentin, Livio, additional, Pietrasanta, Daniela, additional, Innocenti, Idanna, additional, and Laurenti, Luca, additional

Published
2022
Full Text
View/download PDF

77. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Author

Visentin, Andrea, Scarfo, Lydia, Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Demosthenous, Christos, Karakatsoulis, Georgios, Andres, Martin, Antic, Darko, Allsup, David, Baile, Monica, Bron, Dominique, Capasso, Antonella, Catherwood, Mark, Collado, Rosa, Cordoba, Raul, Cuellar-Garcia, Carolina, Delgado, Julio, Dimou, Maria, Doubek, Michael, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Efstathopoulou, Maria, Shimaa, El-Ashwah, Enrico, Alicia, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Furstenau, Moritz, Garcia-Marco, Jose A., Gentile, Massimo, Gimeno, Eva, Maria, Gomes da Silva, Gutwein, Odit, Hakobyan, Yervand, Herishanu, Yair, Hernandez, Jose Angel, Herold, Tobias, Iyengar, Sunil, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga, Kalicinska, Elzbieta, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Palomanes, Juan Marquet, Mattsson, Mattias, Mauro, Francesca Romana, Mayor-Bastida, Carlota, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Milosevic, Ivana, Calvo, Fatima Miras, Niemann, Carsten Utoft, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga S., Pocali, Barbara, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, te Raa, Doreen, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Shrestha, Amit, Simkovic, Martin, Spacek, Martin, Sportoletti, Paolo, Ciocan, Oana Stanca, Tadmor, Tamar, Vandenberghe, Elisabeth, Varettoni, Marzia, Vitale, Candida, Van der Spek, Ellen, Van Gelder, Michel, Wasik-Szczepanek, Ewa, Yanez, Lucrecia, Yassin, Mohamed A., Coscia, Marta, Eichhorst, Barbara, Rambaldi, Alessandro, Stavroyianni, Niki, Trentin, Livio, Stamatopoulos, Kostas, Ghia, Paolo, Visentin, Andrea, Scarfo, Lydia, Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Demosthenous, Christos, Karakatsoulis, Georgios, Andres, Martin, Antic, Darko, Allsup, David, Baile, Monica, Bron, Dominique, Capasso, Antonella, Catherwood, Mark, Collado, Rosa, Cordoba, Raul, Cuellar-Garcia, Carolina, Delgado, Julio, Dimou, Maria, Doubek, Michael, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Efstathopoulou, Maria, Shimaa, El-Ashwah, Enrico, Alicia, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Furstenau, Moritz, Garcia-Marco, Jose A., Gentile, Massimo, Gimeno, Eva, Maria, Gomes da Silva, Gutwein, Odit, Hakobyan, Yervand, Herishanu, Yair, Hernandez, Jose Angel, Herold, Tobias, Iyengar, Sunil, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga, Kalicinska, Elzbieta, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Palomanes, Juan Marquet, Mattsson, Mattias, Mauro, Francesca Romana, Mayor-Bastida, Carlota, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Milosevic, Ivana, Calvo, Fatima Miras, Niemann, Carsten Utoft, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga S., Pocali, Barbara, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, te Raa, Doreen, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Shrestha, Amit, Simkovic, Martin, Spacek, Martin, Sportoletti, Paolo, Ciocan, Oana Stanca, Tadmor, Tamar, Vandenberghe, Elisabeth, Varettoni, Marzia, Vitale, Candida, Van der Spek, Ellen, Van Gelder, Michel, Wasik-Szczepanek, Ewa, Yanez, Lucrecia, Yassin, Mohamed A., Coscia, Marta, Eichhorst, Barbara, Rambaldi, Alessandro, Stavroyianni, Niki, Trentin, Livio, Stamatopoulos, Kostas, and Ghia, Paolo

Published
2022

78. Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study

Author

Fresa, Alberto, Autore, Francesco, Piciocchi, Alfonso, Catania, Gioacchino, Visentin, Andrea, Tomasso, Annamaria, Moretti, Marina, Vitale, Candida, Chiarenza, Annalisa, Morelli, Francesca, Sportoletti, Paolo, Marasca, Roberto, Sapienza, Giuseppe, Cuccaro, Annarosa, Murru, Roberta, Sanna, Alessandro, Patti, Caterina, Angeletti, Ilaria, Coscia, Marta, Trentin, Livio, Pietrasanta, Daniela, Innocenti, Idanna, Laurenti, Luca, Laurenti, Luca (ORCID:0000-0002-8327-1396), Fresa, Alberto, Autore, Francesco, Piciocchi, Alfonso, Catania, Gioacchino, Visentin, Andrea, Tomasso, Annamaria, Moretti, Marina, Vitale, Candida, Chiarenza, Annalisa, Morelli, Francesca, Sportoletti, Paolo, Marasca, Roberto, Sapienza, Giuseppe, Cuccaro, Annarosa, Murru, Roberta, Sanna, Alessandro, Patti, Caterina, Angeletti, Ilaria, Coscia, Marta, Trentin, Livio, Pietrasanta, Daniela, Innocenti, Idanna, Laurenti, Luca, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

N/A

Published
2022

79. Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement

Author

Zinzani, Pier Luigi, Martelli, Maurizio, Ferrero, S, Gentile, Massimo, Laurenti, Luca, Romana Mauro, Francesca, Sportoletti, Paolo, Tedeschi, Alessandra, Varettoni, M, Visco, Carlo, Laurenti, Luca (ORCID:0000-0002-8327-1396), Zinzani, Pier Luigi, Martelli, Maurizio, Ferrero, S, Gentile, Massimo, Laurenti, Luca, Romana Mauro, Francesca, Sportoletti, Paolo, Tedeschi, Alessandra, Varettoni, M, Visco, Carlo, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

The introduction of Bruton's tyrosine kinase (BTK) inhibitors transformed the management of patients with mantle cell lymphoma (MCL). Ibrutinib, the first-in-class BTK inhibitor is now approved in more than 80 countries and there are over 20 new BTK inhibitors in development. In addition, novel agents show potential clinical activity (alone and in combination) and are in the approval phase and/or being studied in ongoing clinical trials. How does the practicing clinician decide on the optimal therapeutic strategy for this highly heterogenous disease? In July 2020 a group of experts from Italy, convened a meeting to address and provide clarification on a series of outstanding issues in the treatment of MCL with the view of providing clinical guidance on its management. This expert opinion statement represents the panel's collective analysis, evaluation, and recommendations and is made up of a series of questions and answers (in the form of a review of the pertinent literature) designed to replicate those posed by practicing clinicians in Italy but which are applicable to clinical settings worldwide.

Published
2022

80. Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement

Author

Ferrero, S, Gentile, Massimo, Laurenti, Luca, Mauro, Francesca Romana, Martelli, Maurizio, Sportoletti, Paolo, Visco, Carlo, Zinzani, Pier Luigi, Tedeschi, Alessandra, Varettoni, M, Laurenti, Luca (ORCID:0000-0002-8327-1396), Ferrero, S, Gentile, Massimo, Laurenti, Luca, Mauro, Francesca Romana, Martelli, Maurizio, Sportoletti, Paolo, Visco, Carlo, Zinzani, Pier Luigi, Tedeschi, Alessandra, Varettoni, M, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

The pivotal role that ibrutinib plays in the management of Waldenström macroglobulinemia (WM) is undisputed but there are ongoing questions regarding its positioning in the therapeutic algorithm of WM as well as in some peculiar clinical situations. A panel of experts from Italy was convened to provide real world recommendations on the use of BTK inhibitors in lymphoproliferative diseases in general, and in patients with WM in particular. This position paper represents the panel's collective analysis, evaluation, and opinions and is made up of a series of questions frequently asked by practicing clinicians and answers based on currently available evidence.

Published
2022

81. Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study

Author

Visentin, Andrea, Mauro, Francesca Romana, Cibien, Francesca, Vitale, Candida, Reda, Gianluigi, Fresa, Alberto, Ciolli, Stefania, Pietrasanta, Daniela, Marchetti, Monia, Murru, Roberta, Gentile, Massimo, Rigolin, Gian Matteo, Quaglia, Francesca Maria, Scarfò, Lydia, Sportoletti, Paolo, Pravato, Stefano, Piazza, Francesco, Coscia, Marta, Laurenti, Luca, Molica, Stefano, Foà, Robin, Cuneo, Antonio, Trentin, Livio, Laurenti, Luca (ORCID:0000-0002-8327-1396), Visentin, Andrea, Mauro, Francesca Romana, Cibien, Francesca, Vitale, Candida, Reda, Gianluigi, Fresa, Alberto, Ciolli, Stefania, Pietrasanta, Daniela, Marchetti, Monia, Murru, Roberta, Gentile, Massimo, Rigolin, Gian Matteo, Quaglia, Francesca Maria, Scarfò, Lydia, Sportoletti, Paolo, Pravato, Stefano, Piazza, Francesco, Coscia, Marta, Laurenti, Luca, Molica, Stefano, Foà, Robin, Cuneo, Antonio, Trentin, Livio, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

NA

Published
2022

82. How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia

Author

Deodato, Marina, Frustaci, Anna Maria, Sportoletti, Paolo, Laurenti, Luca, Murru, Roberta, Visentin, Andrea, Reda, Gianluigi, Mauro, Francesca Romana, Quaresmini, Giulia, Vanazzi, Anna, Vitale, Candida, Orsucci, Lorella, Massaia, Massimo, Sanna, Alessandro, Motta, Marina, Ibatici, Adalberto, Ferrarini, Isacco, Borella, Chiara, Varettoni, Marzia, Tani, Monica, Marinoni, Sara, Ferrario, Andrea, Zamprogna, Giulia, Montillo, Marco, Tedeschi, Alessandra, Laurenti, Luca (ORCID:0000-0002-8327-1396), Deodato, Marina, Frustaci, Anna Maria, Sportoletti, Paolo, Laurenti, Luca, Murru, Roberta, Visentin, Andrea, Reda, Gianluigi, Mauro, Francesca Romana, Quaresmini, Giulia, Vanazzi, Anna, Vitale, Candida, Orsucci, Lorella, Massaia, Massimo, Sanna, Alessandro, Motta, Marina, Ibatici, Adalberto, Ferrarini, Isacco, Borella, Chiara, Varettoni, Marzia, Tani, Monica, Marinoni, Sara, Ferrario, Andrea, Zamprogna, Giulia, Montillo, Marco, Tedeschi, Alessandra, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

NA

Published
2022

83. Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model

Author

Molica, Stefano, Giannarelli, Diana, Visentin, Andrea, Reda, Gianluigi, Sportoletti, Paolo, Frustaci, Anna Maria, Chiarenza, Annalisa, Ciolli, Stefania, Vitale, Candida, Laurenti, Luca, De Paoli, Lorenzo, Murru, Roberta, Gentile, Massimo, Moia, Riccardo, Rigolin, Gian Matteo, Levato, Luciano, Giordano, Annamaria, Del Poeta, Giovanni, Stelitano, Caterina, Deodato, Marina, Ielo, Claudia, Noto, Alessandro, Guarente, Valerio, Coscia, Marta, Tedeschi, Alessandra, Gaidano, Gianluca, Cuneo, Antonio, Foa, Robin, Trentin, Livio, Mauro, Francesca Romana, Laurenti, Luca (ORCID:0000-0002-8327-1396), Foa', Robin, Molica, Stefano, Giannarelli, Diana, Visentin, Andrea, Reda, Gianluigi, Sportoletti, Paolo, Frustaci, Anna Maria, Chiarenza, Annalisa, Ciolli, Stefania, Vitale, Candida, Laurenti, Luca, De Paoli, Lorenzo, Murru, Roberta, Gentile, Massimo, Moia, Riccardo, Rigolin, Gian Matteo, Levato, Luciano, Giordano, Annamaria, Del Poeta, Giovanni, Stelitano, Caterina, Deodato, Marina, Ielo, Claudia, Noto, Alessandro, Guarente, Valerio, Coscia, Marta, Tedeschi, Alessandra, Gaidano, Gianluca, Cuneo, Antonio, Foa, Robin, Trentin, Livio, Mauro, Francesca Romana, Laurenti, Luca (ORCID:0000-0002-8327-1396), and Foa', Robin

Abstract

NA

Published
2022

84. T regulatory cell separation for clinical application

Author

Di Ianni, Mauro, Del Papa, Beatrice, Zei, Tiziana, Iacucci Ostini, Roberta, Cecchini, Debora, Cantelmi, Maria Grazia, Baldoni, Stefano, Sportoletti, Paolo, Cavalli, Laura, Carotti, Alessandra, Pierini, Antonio, Falini, Brunangelo, Martelli, Massimo F., and Falzetti, Franca

Published
2012
Full Text
View/download PDF

85. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and COVID-19: A study of ERIC, the European Research Initiative on CLL

Author

Antic, Darko, primary, Milic, Natasa, additional, Chatzikonstantinou, Thomas, additional, Scarfò, Lydia, additional, Otasevic, Vladimir, additional, Rajovic, Nina, additional, Allsup, David, additional, Cabrero, Alejandro Alonso, additional, Andres, Martin, additional, Gonzales, Monica Baile, additional, Capasso, Antonella, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Correa, Juan Gonzalo, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Poeta, Giovanni Del, additional, Dimou, Maria, additional, Doubek, Michael, additional, Efstathopoulou, Maria, additional, El-Ashwah, Shaimaa, additional, Enrico, Alicia, additional, Espinet, Blanca, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Lopez-Garcia, Alberto, additional, García-Marco, José A., additional, García-Serra, Rocío, additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Silva, Maria Gomes, additional, Gutwein, Odit, additional, Hakobyan, Yervand K., additional, Herishanu, Yair, additional, Hernández-Rivas, José Ángel, additional, Herold, Tobias, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Оlga B., additional, Kalicińska, Elżbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Koren-Michowitz, Maya, additional, Gomez, Jorge Labrador, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Fresa, Alberto, additional, Levin, Mark-David, additional, Bastida, Carlota Mayor, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet, Juan, additional, Mihaljevic, Biljana, additional, Milosevic, Ivana, additional, Mirás, Fatima, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Nunes, Raquel, additional, Olivieri, Jacopo, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Smirnova, Svetlana, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca, Oana, additional, Stavroyianni, Niki, additional, Raa, Doreen Te, additional, Tomic, Kristina, additional, Tonino, Sanne, additional, Trentin, Livio, additional, Spek, Ellen Der, additional, Gelder, Michel, additional, Varettoni, Marzia, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Vukovic, Vojin, additional, Wasik-Szczepanek, Ewa, additional, Wróbel, Tomasz, additional, Segundo, Lucrecia Yáñez San, additional, Yassin, Mohamed, additional, Coscia, Marta, additional, Rambaldi, Alessandro, additional, Montserrat, Emili, additional, Foà, Robin, additional, Cuneo, Antonio, additional, Carrier, Marc, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2022
Full Text
View/download PDF

86. How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia

Author

Deodato, Marina, primary, Frustaci, Anna Maria, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Murru, Roberta, additional, Visentin, Andrea, additional, Reda, Gianluigi, additional, Mauro, Francesca Romana, additional, Quaresmini, Giulia, additional, Vanazzi, Anna, additional, Vitale, Candida, additional, Orsucci, Lorella, additional, Massaia, Massimo, additional, Sanna, Alessandro, additional, Motta, Marina, additional, Ibatici, Adalberto, additional, Ferrarini, Isacco, additional, Borella, Chiara, additional, Varettoni, Marzia, additional, Tani, Monica, additional, Marinoni, Sara, additional, Ferrario, Andrea, additional, Zamprogna, Giulia, additional, Montillo, Marco, additional, and Tedeschi, Alessandra, additional

Published
2022
Full Text
View/download PDF

89. sj-docx-1-tah-10.1177_20406207221127550 – Supplemental material for Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia

Author

Frustaci, Anna Maria, Del Poeta, Giovanni, Visentin, Andrea, Sportoletti, Paolo, Fresa, Alberto, Vitale, Candida, Murru, Roberta, Chiarenza, Annalisa, Sanna, Alessandro, Mauro, Francesca Romana, Reda, Gianluigi, Gentile, Massimo, Varettoni, Marzia, Baratè, Claudia, Borella, Chiara, Greco, Antonino, Deodato, Marina, Zamprogna, Giulia, Laureana, Roberta, Cipiciani, Alessandra, Galitzia, Andrea, Curto Pelle, Angelo, Morelli, Francesca, Malvisi, Lucio, Coscia, Marta, Laurenti, Luca, Trentin, Livio, Montillo, Marco, Cairoli, Roberto, and Tedeschi, Alessandra

Subjects
FOS: Clinical medicine, Cardiology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tah-10.1177_20406207221127550 for Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia by Anna Maria Frustaci, Giovanni Del Poeta, Andrea Visentin, Paolo Sportoletti, Alberto Fresa, Candida Vitale, Roberta Murru, Annalisa Chiarenza, Alessandro Sanna, Francesca Romana Mauro, Gianluigi Reda, Massimo Gentile, Marzia Varettoni, Claudia Baratè, Chiara Borella, Antonino Greco, Marina Deodato, Giulia Zamprogna, Roberta Laureana, Alessandra Cipiciani, Andrea Galitzia, Angelo Curto Pelle, Francesca Morelli, Lucio Malvisi, Marta Coscia, Luca Laurenti, Livio Trentin, Marco Montillo, Roberto Cairoli and Alessandra Tedeschi in Therapeutic Advances in Hematology

Published
2022
Full Text
View/download PDF

90. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation

Author

Di Ianni, Mauro, Falzetti, Franca, Carotti, Alessandra, Terenzi, Adelmo, Castellino, Flora, Bonifacio, Elisabetta, Del Papa, Beatrice, Zei, Tiziana, Ostini, Roberta Iacucci, Cecchini, Debora, Aloisi, Teresa, Perruccio, Katia, Ruggeri, Loredana, Balucani, Chiara, Pierini, Antonio, Sportoletti, Paolo, Aristei, Cynthia, Falini, Brunangelo, Reisner, Yair, Velardi, Andrea, Aversa, Franco, and Martelli, Massimo F.

Published
2011
Full Text
View/download PDF

93. Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three‐factor model

Author

Molica, Stefano, primary, Giannarelli, Diana, additional, Visentin, Andrea, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Frustaci, Anna Maria, additional, Chiarenza, Annalisa, additional, Ciolli, Stefania, additional, Vitale, Candida, additional, Laurenti, Luca, additional, De Paoli, Lorenzo, additional, Murru, Roberta, additional, Gentile, Massimo, additional, Moia, Riccardo, additional, Rigolin, Gian Matteo, additional, Levato, Luciano, additional, Giordano, Annamaria, additional, Del Poeta, Giovanni, additional, Stelitano, Caterina, additional, Deodato, Marina, additional, Ielo, Claudia, additional, Noto, Alessandro, additional, Guarente, Valerio, additional, Coscia, Marta, additional, Tedeschi, Alessandra, additional, Gaidano, Gianluca, additional, Cuneo, Antonio, additional, Foa', Robin, additional, Trentin, Livio, additional, and Mauro, Francesca Romana, additional

Published
2022
Full Text
View/download PDF

94. Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia

Author

Frustaci, Anna Maria, primary, Del Poeta, Giovanni, additional, Visentin, Andrea, additional, Sportoletti, Paolo, additional, Fresa, Alberto, additional, Vitale, Candida, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Sanna, Alessandro, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Gentile, Massimo, additional, Varettoni, Marzia, additional, Baratè, Claudia, additional, Borella, Chiara, additional, Greco, Antonino, additional, Deodato, Marina, additional, Zamprogna, Giulia, additional, Laureana, Roberta, additional, Cipiciani, Alessandra, additional, Galitzia, Andrea, additional, Curto Pelle, Angelo, additional, Morelli, Francesca, additional, Malvisi, Lucio, additional, Coscia, Marta, additional, Laurenti, Luca, additional, Trentin, Livio, additional, Montillo, Marco, additional, Cairoli, Roberto, additional, and Tedeschi, Alessandra, additional

Published
2022
Full Text
View/download PDF

95. Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study

Author

Mauro, Francesca Romana, primary, Paoloni, Francesca, additional, Molica, Stefano, additional, Reda, Gianluigi, additional, Trentin, Livio, additional, Sportoletti, Paolo, additional, Marchetti, Monia, additional, Pietrasanta, Daniela, additional, Marasca, Roberto, additional, Gaidano, Gianluca, additional, Coscia, Marta, additional, Stelitano, Caterina, additional, Mannina, Donato, additional, Di Renzo, Nicola Di, additional, Ilariucci, Fiorella, additional, Liberati, Anna Marina, additional, Orsucci, Lorella, additional, Re, Francesca, additional, Tani, Monica, additional, Musuraca, Gerardo, additional, Gottardi, Daniela, additional, Zinzani, Pier Luigi, additional, Gozzetti, Alessandro, additional, Molinari, Annalia, additional, Gentile, Massimo, additional, Chiarenza, Annalisa, additional, Laurenti, Luca, additional, Varettoni, Marzia, additional, Ibatici, Adalberto, additional, Murru, Roberta, additional, Ruocco, Valeria, additional, Del Giudice, Ilaria Del, additional, De Propris, Maria Stefania De, additional, Della Starza, Irene Della, additional, Raponi, Sara, additional, Nanni, Mauro, additional, Fazi, Paola, additional, Neri, Antonino, additional, Guarini, Anna, additional, Rigolin, Gian Matteo, additional, Piciocchi, Alfonso, additional, Cuneo, Antonio, additional, and Foà, Robin, additional

Published
2021
Full Text
View/download PDF

96. Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML

Author

Martelli, Maria Paola, primary, Rossi, Roberta, additional, Venanzi, Alessandra, additional, Meggendorfer, Manja, additional, Perriello, Vincenzo Maria, additional, Martino, Giovanni, additional, Spinelli, Orietta, additional, Ciurnelli, Raffaella, additional, Varasano, Emanuela, additional, Brunetti, Lorenzo, additional, Ascani, Stefano, additional, Quadalti, Corinne, additional, Cardinali, Valeria, additional, Mezzasoma, Federica, additional, Gionfriddo, Ilaria, additional, Milano, Francesca, additional, Pacini, Roberta, additional, Tabarrini, Alessia, additional, Bigerna, Barbara, additional, Albano, Francesco, additional, Specchia, Giorgina, additional, Vetro, Calogero, additional, Di Raimondo, Francesco, additional, Annibali, Ombretta, additional, Avvisati, Giuseppe, additional, Rambaldi, Alessandro, additional, Falzetti, Franca, additional, Tiacci, Enrico, additional, Sportoletti, Paolo, additional, Haferlach, Torsten, additional, Haferlach, Claudia, additional, and Falini, Brunangelo, additional

Published
2021
Full Text
View/download PDF

97. Continuous treatment with Ibrutinib in 100 untreated patients with TP 53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study

Author

Visentin, Andrea, primary, Mauro, Francesca Romana, additional, Cibien, Francesca, additional, Vitale, Candida, additional, Reda, Gianluigi, additional, Fresa, Alberto, additional, Ciolli, Stefania, additional, Pietrasanta, Daniela, additional, Marchetti, Monia, additional, Murru, Roberta, additional, Gentile, Massimo, additional, Rigolin, Gian Matteo, additional, Quaglia, Francesca Maria, additional, Scarfò, Lydia, additional, Sportoletti, Paolo, additional, Pravato, Stefano, additional, Piazza, Francesco, additional, Coscia, Marta, additional, Laurenti, Luca, additional, Molica, Stefano, additional, Foà, Robin, additional, Cuneo, Antonio, additional, and Trentin, Livio, additional

Published
2021
Full Text
View/download PDF

99. Prolonged XPO1 inhibition is essential for optimal anti-leukemic activity in NPM1-mutated AML

Author

Pianigiani, Giulia, primary, Gagliardi, Andrea, additional, Mezzasoma, Federica, additional, Rocchio, Francesca, additional, Tini, Valentina, additional, Bigerna, Barbara, additional, Sportoletti, Paolo, additional, Caruso, Simona, additional, Marra, Andrea, additional, Spinozzi, Giulio, additional, Shacham, Sharon, additional, Landesman, Yosef, additional, Quintarelli, Concetta, additional, Locatelli, Franco, additional, Martelli, Maria Paola, additional, Falini, Brunangelo, additional, and Brunetti, Lorenzo, additional

Published
2021
Full Text
View/download PDF

100. Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real‐World" study.

Author

Levi, Shai, Bronstein, Yotam, Goldschmidt, Neta, Morabito, Fortunato, Ziv‐Baran, Tomer, Del Poeta, Giovanni, Bairey, Osnat, Del Principe, Maria Ilaria, Fineman, Riva, Mauro, Francesca Romana, Gutwein, Odit, Reda, Gianluigi, Ruchlemer, Rosa, Sportoletti, Paolo, Laurenti, Luca, Shvidel, Lev, Coscia, Marta, Tadmor, Tamar, Varettoni, Marzia, and Aviv, Ariel

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results